Frontlight ResearchEarly access
CompletedPhase 1
Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)
Key facts
- Who runs it
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Where
- Baltimore, Cleveland, and Mayfield Heights, United StatesSee the 4 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 15 people enrolled
- Started
- 17 Apr 2019
- Ended
- 3 Dec 2024
- Type of study
- Interventional, 3 groups
- Treatments tested
- artesunate ointment 40%
- Record updated
- 4 December 2024
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Colposcopically-directed biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2/3, HSIL), including both new and recurrent disease
- Females of childbearing potential: negative urine pregnancy test
- Ability to provide informed consent
- Ability to collaborate with planned follow-up (transportation, compliance history, etc.)
- Use of contraception through the study exit visit (week 28)
Who cannot take part
- Concomitant use of any topical immune modulating agents e.g. imiquimod, Aldara ®
- Currently receiving systemic chemotherapy or radiation therapy for another cancer
- Concurrent dermatological disorders involving the vulva (i.e., herpes, ulceration secondary to Crohn's disease) or vulvar dermatosis (i.e., lichen planus, lichen sclerosus, or lichen simplex chronicus)
- Cluster of differentiation 4 (CD4) count < 200 at the time of screening for eligibility
- Unable to provide informed consent
- Pregnant females
- Women weighing less than 50 kg
Where in United States
- Johns Hopkins Outpatient CenterBaltimore, United States
- Cleveland Clinic Fairview HospitalCleveland, United States
- Cleveland Clinic Foundation Main CampusCleveland, United States
- Cleveland Clinic - Hillcrest HospitalMayfield Heights, United States
About the trial
What the trial wants to find out
This is a Phase I, proof-of-concept treatment study to evaluate the safety, tolerability and feasibility of topical artesunate ointment to treat high grade vulvar intraepithelial neoplasia (HSIL VIN2/3).
The 3 groups in the trial
- Artesunate ointment 40%, 1 cycleTreatment being tested
Patients enrolled in this treatment group will receive one 5-day cycle of artesunate ointment applied topically to the vulva at week 0.
Treatment: artesunate ointment 40%
- Artesunate ointment 40%, 2 cyclesTreatment being tested
Patients enrolled in this treatment group will receive two 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0 and 2.
Treatment: artesunate ointment 40%
- Artesunate ointment 40%, 3 cyclesTreatment being tested
Patients enrolled in this treatment group will receive three 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0, 2, and 4.
Treatment: artesunate ointment 40%
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I Proof-of-Concept Study of Artesunate Ointment for the Treatment of Patients With High-Grade Vulvar Intraepithelial Neoplasia (HSIL VIN 2/3)
- Record updated
- 4 December 2024